These overlooked global diseases take a turn under the microscope
Faculty at the School of Veterinary Medicine target neglected tropical diseases with advanced science, cross-disciplinary collaborations, and work in the lab and the field.
Positive results in first-in-U.S. trial of CRISPR-edited immune cells
Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.
To monitor cancer therapy, researchers tag CAR T cells with imaging markers
With CAR T cell therapy, a patient’s own immune cells are genetically modified and inserted back into the body to find and kill cancer. Now scientists have now discovered a new way to track CAR T cells in the body.
Researchers unravel the early makings of an exhausted T cell
Knowing which T cells will lose the battle against cancer earlier could inform treatments and the development of new immunotherapies.
Algorithm personalizes which cancer mutations are best targets for immunotherapy
A new model developed by researchers in the Abramson Cancer Center hand-picks cancer cells to target for more effective, customized cancer vaccines.
CAR T cell therapy may be harnessed to treat heart disease
Penn Med researchers used genetically modified T cells to improve heart function in an animal model after cardiac injury, a step forward in expanding the use of the technology to treating, or even reversing, heart failure.
Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy
A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies.
Elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
A Penn study of Medicare patients who are often underrepresented in medical trials finds overall survival benefits from treatment with targeted therapies.
How to reinvigorate exhausted immune cells to stop cancer
A Penn study has identified a protein called TOX that regulates exhausted T-cells, and could be a key to new immunotherapies.
For melanoma patients, one dose of immunotherapy before surgery can lead to remission
An Abramson Cancer Center study finds that with a single dose of a PD-1 inhibitor, immune responses can peak in just one week.